Herbalife (HLF) Pushes to Highs as Icahn Looks to Trigger Ackman Short Squeeze
- Wall St. gains across sectors ahead of Trump inauguration
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
- Investment Focus: History suggests Trump month will be stocks down, dollar up
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Herbalife (NYSE: HLF) is pushing to the highs of the session, which follows comments from Carl Icahn at CNBC's Delivering Alpha conference yesterday that he has sought FTC approval to raise his stake to 50%. In addition, Icahn said the company would made a great 'take private' candidate.
It is clear, Carl Icahn is looking to create a Bill Ackman short squeeze.
Shares of HLF are up 4.6% to $62.64.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) $1.175B Cov-Lite 7Y 1L TL for Refi, $150m RCF; Bank Meeting Jan. 20 - Bloomberg
- Bristol-Myers Squibb (BMY) volatility low into saying it won’t seek accelerated approval for lung cancer combination treatment
Create E-mail Alert Related CategoriesHedge Funds, Short Sales, Trader Talk
Related EntitiesCarl Icahn, William Ackman
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!